Please login to the form below
Mereo BioPharma’s Richard Bungay to step down
Will leave CFO and COO roles in April 2017
Mereo BioPharma's Richard Bungay is set to step down from his roles as chief financial officer and chief operating officer in April 2017.
Bungay joined the UK-based clinical stage biopharmaceutical firm in July last year, taking on responsibility for Mereo BioPharma's finances, manufacturing and quality operations.
He has previously held the chief financial title at Glide Pharmaceutical Technologies, Chroma Therapeutics and Verona Pharma, remaining as a non-executive board director at both Glide and Chroma.
Prior to these roles, Bungay worked at Celltech Group as director of corporate communications and planning, and served as finance director for AstraZeneca's respiratory and inflammation therapy area.
Dr Peter Fellner, chairman of Mereo BioPharma, said: “On behalf of the board I would like to thank Richard for his significant contributions to the successful launch of the company and the subsequent introduction of its shares on AIM.
“We wish him every success for the future.”
Featured jobs
-
Senior Medical Writer
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Director, Medical Education
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Director
-
Competitive Salary Offered
-
Business Director
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
-
Medical Writer
-
Salary TBC
Subscribe to our email news alerts
- China’s clinical trial shake-up
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
PMHub
Dovetail
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...
Latest intelligence
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
Quick links
Infographics
